Vuijk SA, Jongsma MME, Hoeven BM, Cozijnsen MA, et al. Randomised clinical trial: First-line infliximab biosimilar is cost-effective compared to conventional treatment in paediatric Crohn's disease. Aliment Pharmacol Ther 2024 Apr 21. doi: 10.1111/apt.18000.
PMID: 38644588